The Pittsburgh Technology Council celebrated the 25th annual Tech 50 Awards on Nov. 10, 2021 to honor the fastest growing and most innovative technology companies, service providers and CEOS in the Pittsburgh region.
PITTSBURGH, April 24, 2025–(BUSINESS WIRE)–CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, core cohort dose-limiting toxicity observation…
The Pittsburgh Technology Council’s Tech 50 Awards honors technology innovation in our region. On Thursday, November 14, 2024, we will celebrate the most successful and innovative companies in Southwestern Pennsylvania at the 28th annual Tech…
CytoAgents Inc. (the Company), a clinical-stage biotechnology company, dedicated to developing a safe and effective treatment for Cytokine Release Syndrome (CRS), announced today that it has been awarded a $2 million National Institutes of Health…